Vitamin D and Glucose Metabolism in Pediatrics - Full Text View

Purpose

The discovery that the vitamin D receptor is expressed in more than 30 tissues indicates that the physiologic functions of vitamin D are much broader than its well-known role in the regulation of calcium absorption and bone metabolism. There is evidence that vitamin D is involved in the pathogenesis of cancer, cardiovascular disease, multiple sclerosis, and type I diabetes. Recent epidemiological evidence points to a strong association between vitamin D insufficiency and insulin resistance, the metabolic syndrome, and type II diabetes. The investigators would like to examine the role of vitamin D in the development of insulin resistance in overweight children and adolescents, which represent a high risk population for cardiovascular and metabolic complications. The investigators propose a prospective randomized clinical trial of vitamin D supplementation in overweight, insulin resistant, vitamin D deficient children. The investigators objective is to assess if changes in insulin resistance, fasting lipid profiles, blood pressure, and inflammatory markers occur in these patients post treatment with vitamin D. Additionally, concomitant changes in calcium and bone metabolism after vitamin D treatment will be evaluated. This is because, contrary to adults, the optimal vitamin D concentrations that regulate calcium and bone metabolism have not been established in pediatrics.

Condition	Intervention	Phase
Insulin Resistance Obesity Vitamin D25 Insufficiency	Drug: Vitamin D drops Drug: Placebo drops	Phase 4


Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Prevention
Official Title:	Vitamin D Concentrations and Their Effect on Glucose Metabolism in Pediatrics

Resource links provided by NLM:

MedlinePlus related topics: Children's Health Vitamin D

Drug Information available for: Vitamin D

U.S. FDA Resources

Further study details as provided by Weill Medical College of Cornell University:

Primary Outcome Measures:

To determine changes in insulin sensitivity induced by vitamin D supplementation in obese children with insulin resistance. [ Time Frame: 4 months ] [ Designated as safety issue: No ]
To our knowledge, there are no prospective randomized clinical trials on examining the effects of vitamin D treatment on insulin resistance and bone metabolism in vitamin D deficient, insulin resistant, obese children. We would like to determine if giving Vitamin D supplementation to obese children will help reduce their insulin resistance. We plan to measure Vitamin D levels and HOMA-IR at baseline and compare this to levels post-supplementation. Our timeframe is baseline and 4 months.

Secondary Outcome Measures:

To quantify the associations between vitamin D 25 concentration, insulin resistance, and calcium metabolism in overweight children. [ Time Frame: 4 months ] [ Designated as safety issue: No ]
The normal values for vitamin D are not standardized. In children, it is generally accepted, that vitamin D25 levels>20ng/ml are indicative of vitamin D sufficiency. Data in adults, however, suggest that this cutoff for vitamin D sufficiency should be raised to greater than 30ng/ml. Analysis of bone metabolism in this study will give some insight to the effects of vitamin D treatment in this population of children, and may help further define acceptable vitamin D levels in determining vitamin D deficiency and insufficiency. Our timeframe is baseline and 4 months.


Estimated Enrollment:	110
Study Start Date:	April 2011
Estimated Study Completion Date:	March 2012
Estimated Primary Completion Date:	March 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Active Comparator: Vitamin D Subjects will randomly be assigned to Vitamin D drops versus placebo drops.	Drug: Vitamin D drops Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
Placebo Comparator: Placebo Subjects will randomly be assigned to Vitamin D drops versus placebo drops.	Drug: Placebo drops Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.

Eligibility


Ages Eligible for Study:	7 Years to 18 Years (Child, Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

BMI>85th% for age & sex
Vitamin D25 between 10-20ng/ml
Normal serum Ca concentrations >8.5mg/dl
Evidence of insulin resistance (measured by HOMA-IR, and QUICKI indices)

Exclusion Criteria:

Vitamin D25<10ng/ml
No parental consent
No evidence of insulin resistance
BMI < 85th percentile
Known diagnosis of type 1 or 2 diabetes
Severe underlying disease such as liver disease, end-stage renal disease, or malignancy
Present medication that affects insulin sensitivity such as steroids or Metformin
Any chronic illness or administration of medications that is associated with fat malabsorption as they may interfere with vitamin D absorption.
Known history of hypocalcemia, calcium disorder (such as Di George syndrome)
Serum Calcium concentration < 8.5mg/dl
Other drugs that might effect vitamin D metabolism due to induction of P450 enzyme activity.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01386736

Contacts


Contact: Maria Vogiatzi, MD	212-746-3462	mvogiatz@med.cornell.edu
Contact: Sadana Balachandar, MD	212-746-3462	sab9082@nyp.org

Locations


United States, New York
Weill Cornell Medical College	Recruiting
New York, New York, United States, 10021
Contact: Sadana Balachandar, MD 212-746-3462 sab9082@nyp.org
Principal Investigator: Maria Vogiatzi, MD

Sponsors and Collaborators

Weill Medical College of Cornell University

Investigators


Principal Investigator:	Maria Vogiatzi, MD	Weill Medical College of Cornell University

More Information

Publications:

Alemzadeh R, Kichler J, Babar G, Calhoun M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism. 2008 Feb;57(2):183-91. doi: 10.1016/j.metabol.2007.08.023.

Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266-81. Review.

Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004 May;79(5):820-5.

Smotkin-Tangorra M, Purushothaman R, Gupta A, Nejati G, Anhalt H, Ten S. Prevalence of vitamin D insufficiency in obese children and adolescents. J Pediatr Endocrinol Metab. 2007 Jul;20(7):817-23.

Munns C, Zacharin MR, Rodda CP, Batch JA, Morley R, Cranswick NE, Craig ME, Cutfield WS, Hofman PL, Taylor BJ, Grover SR, Pasco JA, Burgner D, Cowell CT; Paediatric Endocrine Group; Paediatric Bone Australasia. Prevention and treatment of infant and childhood vitamin D deficiency in Australia and New Zealand: a consensus statement. Med J Aust. 2006 Sep 4;185(5):268-72.

Keskin M, Kurtoglu S, Kendirci M, Atabek ME, Yazici C. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics. 2005 Apr;115(4):e500-3. Epub 2005 Mar 1.

Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, Quon MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000 Jul;85(7):2402-10.

Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999 Sep;22(9):1462-70.

Radikova Z, Koska J, Huckova M, Ksinantova L, Imrich R, Vigas M, Trnovec T, Langer P, Sebokova E, Klimes I. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes. 2006 May;114(5):249-56.

Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab. 2007 Jun;92(6):2017-29. Epub 2007 Mar 27. Review.

Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008 Mar;10(3):185-97. doi: 10.1111/j.1463-1326.2007.00710.x. Review.

Forouhi NG, Luan J, Cooper A, Boucher BJ, Wareham NJ. Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000. Diabetes. 2008 Oct;57(10):2619-25. doi: 10.2337/db08-0593. Epub 2008 Jun 30.


Responsible Party:	Maria Vogiatzi, MD, Weill Cornell Medical College
ClinicalTrials.gov Identifier:	NCT01386736 History of Changes
Other Study ID Numbers:	0902010250
Study First Received:	April 18, 2011
Last Updated:	June 30, 2011
Health Authority:	United States: Institutional Review Board

Keywords provided by Weill Medical College of Cornell University:


insulin resistance obesity adolescence vitamin D supplementation

Additional relevant MeSH terms:


Insulin Resistance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Vitamins Vitamin D	Ergocalciferols Micronutrients Growth Substances Physiological Effects of Drugs Bone Density Conservation Agents

ClinicalTrials.gov processed this record on September 23, 2016